Literature DB >> 23754638

Rational for statin use in psoriatic patients.

Jerzy Mosiewicz1, Aldona Pietrzak, Grażyna Chodorowska, Marcin Trojnar, Jacek Szepietowski, Kristian Reich, Manfredi Rizzo.   

Abstract

Psoriasis represents a common skin disease which is clinically manifested by chronic cutaneous lesions. It has been observed that psoriasis is associated with an increased risk of cardiovascular diseases, which is contributed to the inappropriate lipid metabolism. Statins are commonly used in clinical practice to lower cholesterol concentration and, accordingly, decrease the individual risk of developing a cardiovascular episode. There have been reports that statin administration could also result in better management of psoriasis. The observed beneficial effects are contributed to the effects on lipid metabolism, including that in skin, as well as anti-inflammatory and immunomodulatory properties of statins. Simvastatin and atorvastatin were found to improve the clinical outcome in patients with psoriatic skin lesions. Clinically, the effectiveness of this novel treatment was confirmed by the significant reduction in PASI score. To date several cases have been reported in which atorvastatin or pravastatin worsened psoriasis. Based on these results, it seems that statins represent a promising class of medications which could be extensively used in psoriasis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23754638     DOI: 10.1007/s00403-013-1374-1

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  6 in total

Review 1.  Statin treatment, new-onset diabetes, and other adverse effects: a systematic review.

Authors:  Casper N Bang; Peter M Okin
Journal:  Curr Cardiol Rep       Date:  2014-03       Impact factor: 2.931

2.  Psoriasis in Patients with Metabolic Syndrome or Type 2 Diabetes Mellitus: Treatment Challenges.

Authors:  Sukhmani Pannu; David Rosmarin
Journal:  Am J Clin Dermatol       Date:  2021-02-15       Impact factor: 7.403

3.  Serum Cholesteryl Ester Transfer Protein (CETP) and Sortilin (SORT) in Patients with Psoriasis with Relation to Systemic Treatment.

Authors:  Julia Nowowiejska; Anna Baran; Julita A Krahel; Tomasz W Kamiński; Magdalena Maciaszek; Iwona Flisiak
Journal:  Metabolites       Date:  2022-04-09

Review 4.  Targeting T Cell Metabolism in Inflammatory Skin Disease.

Authors:  Leonhard von Meyenn; Nicole Leonie Bertschi; Christoph Schlapbach
Journal:  Front Immunol       Date:  2019-09-24       Impact factor: 7.561

5.  A Case of Psoriasis Vulgaris Aggravated with Atorvastatin, Aided by Concomitant Cyclosporine.

Authors:  Kenit P Ardeshna; Shylaja Someshwar; Shaurya Rohatgi; Hemangi R Jerajani
Journal:  Indian J Dermatol       Date:  2017 Sep-Oct       Impact factor: 1.494

6.  Antipsychotic-associated psoriatic rash - a case report.

Authors:  Camelia-Eugenia Bujor; Torkel Vang; Jimmi Nielsen; Ole Schjerning
Journal:  BMC Psychiatry       Date:  2017-07-04       Impact factor: 3.630

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.